Gibraltar’s $1.34B plan to acquire OmniMax International boosts its reach in roofing and rainwear, doubling product revenue and promising fast synergies and margin gains. ...
Zymeworks soared 34% after its partnered drug Ziihera posted strong Phase 3 data, with Jazz Pharmaceuticals showing it improved outcomes in a tough cancer — a breakthrough moment for the ...
Bitcoin (BTC) has started December in a slump, extending a multi-week downturn that has lowered confidence across digital asset markets. ...
US stocks struggled on Monday, kicking off December with a turbulent start as Wall Street’s late-November rebound quickly ran into resistance. ...
Genco jumped after a bid from Diana Shipping, which already owns 14.8% and now seeks full control, aiming for fleet synergies, low breakevens, and leverage to improving drybulk markets. ...
Cryptocurrencies edged higher on Thursday, extending a midweek rebound that lifted Bitcoin back above $91,000 and helped ease pressure across digital assets after weeks of volatility. ...
Gold prices surged again on Friday, capping a powerful four-month winning streak and edging toward record highs as expectations for a December rate cut solidified. ...
National CineMedia is acquiring Spotlight Cinema Networks to expand into premium boutique theaters, boosting its national share and strengthening its presence in major markets like NYC and LA. ...
US stocks edged higher in a shortened Black Friday session, closing out a turbulent November with fresh momentum despite lingering worries around tech valuations and the broader economic outlook. ...
Nanox’s planned acquisition of VasoHealthcare IT signals a strategic push to speed U.S. adoption of its AI imaging tech by adding nationwide integration, data migration, and deployment expertise. ...
Genco is adding two modern scrubber-fitted Newcastlemax ships for $145.5M, aiming to boost scale and efficiency as dry bulk supply stays tight and long-haul volumes trend higher. ...
Agios plunged 48% after its Phase III Pyrukynd trial delivered mixed results, missing key pain-crisis and fatigue endpoints. Despite strong hemoglobin gains, AGIO still seeks FDA approval. ...